Who founded Haya Therapeutics?

Haya Therapeutics was founded by Samir Ounzain, Daniel Blessing.

Who are Haya Therapeutics's investors?

Haya Therapeutics's investors include Broadview Ventures, Sofinnova Partners, Apollo Health Ventures, +ND Capital, 4see Ventures, Lifelink, Humboldt.

Haya Therapeutics

7 known investors

Find your way into Haya Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

293 people can intro you to Richard

Ask Daria Balatsky to introduce you to Richard Law

You →Daria · together at OpenEye Scientific Software, Inc. →Richard

73 people can intro you to Samir

Ask Jamie Chen to introduce you to Samir Ounzain

You →Jamie · together at CHUV | Lausanne university hospital →Samir

71 people can intro you to Eric

Ask Sam Okafor to introduce you to Eric Adam

You →Sam · together at FIND, Foundation for Innovative New Diagnostics →Eric

Your email: who you already know at Haya Therapeutics, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Haya Therapeutics team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease. The biotech company builds a regulatory genome platform to discover tissue- and cell-specific lncRNA targets and turn them into oligonucleotide-based therapies.

AI & Machine Learning Biotech Deep Tech Healthtech

Founders & leadership

Samir Ounzain Chief Executive Officer (CEO) & Co-founderSamir Ounzain is Co-founder and CEO of Haya Therapeutics, a clinical-stage biotech company developing RNA-based therapies targeting long non-coding RNAs to treat fibrosis and cardiorenal disease.

Daniel BlessingChief Scientific Officer (CSO) & Co-founder

Richard Law Chief Business Officer (CBO)Richard Law has 25 years of experience as a scientist, manager, and business developer across pharmaceutical and biotechnology companies, academic institutions, and U.S. government roles. He is Chief Business Officer of Haya Therapeutics, which develops RNA-based therapies targeting regulatory genome mechanisms to treat cardiac fibrosis, obesity, and metabolic disease.

Eric Adam Chief Operating Officer (COO)Eric Adam served in strategic planning and leadership roles at Roche overseeing transformation initiatives and portfolio execution, and held positions at Otsuka Pharmaceuticals Japan, Syrrx (Takeda California), and the FIND organization where he led global public-private partnerships in antimicrobial resistance and diagnostic development.

Jordan ShinChief Medical Officer (CMO)

Jérôme AndriesChief Financial Officer (CFO)

Investors · 7

Broadview Ventures✓ confirmed by Haya TherapeuticsBoston

How we know: the company's own site · Broadview Ventures's portfolio page · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

Sofinnova Partners✓ confirmed by Haya TherapeuticsParis · $540K – $27M

How we know: Sofinnova Partners's portfolio page · the company's own site · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

Apollo Health Ventures✓ confirmed by Haya TherapeuticsBerlin

How we know: the company's own site · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

+ND Capitallisted by +ND CapitalWoodside · $540K – $5.4M

4see Ventureslisted by 4see VenturesChêne-Bougeries · $432K – $1.1Mvia Daniel Bertholet · inferred

How we know: 4see Ventures's portfolio page · Not right? Tell us

Lifelinklisted by LifelinkBarcelona

How we know: Lifelink's portfolio page · Not right? Tell us

HumboldtreportedNew York · $100K – $5M

How we know: a partner's Signal profile · Not right? Tell us

Founder mafia

4 people who came through Haya Therapeutics went on to found or lead other companies.

Sudhir AgrawalMember, Scientific Advisory BoardFounded Aldebaran Therapeutics Dr. Jens EcksteinMember Board Of Directors, Interim ChairmanFounded Palleon Pharmaceuticals Brian ThomasExecutive and Chairman of the BoardFounded Metagenomi Denis DryginSVP DevelopmentFounded Pimera

Frequently asked questions

What does Haya Therapeutics do?: HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease. The biotech company builds a regulatory genome platform to discover tissue- and cell-specific lncRNA targets and turn them into oligonucleotide-based therapies.
Who founded Haya Therapeutics?: Haya Therapeutics was founded by Samir Ounzain, Daniel Blessing.
Who are Haya Therapeutics's investors?: Haya Therapeutics's investors include Broadview Ventures, Sofinnova Partners, Apollo Health Ventures, +ND Capital, 4see Ventures, Lifelink, Humboldt.